The GLP-1 Era on the Gym Floor: Pharma's $45B Question for Operators

The numbers behind the GLP-1 era have stopped being a pharma story. Evaluate’s 2026 Preview projects Eli Lilly’s tirzepatide — sold as Mounjaro and Zepbound — to post more than $45 billion in global sales this year, which would make it the best-selling drug on earth, with Novo Nordisk’s semaglutide franchise second at $39.5 billion. For gym operators, the question was never whether the drugs would be big. It is what they do to the membership behaviour of the millions taking them — and the 2026 evidence so far points operators toward redesign, not retreat.

Lilly’s run-rate

Eli Lilly’s second quarter of 2026 shows the scale of the demand: revenue rose 48% to $22.97 billion, with Mounjaro generating $9.9 billion — up 91% in the US and 172% internationally — and Zepbound $4.9 billion, up 46%. Combined, the two tirzepatide brands booked $14.871 billion in a single quarter, and GLP-1 products now account for roughly 65% of company revenue. Lilly raised its full-year 2026 revenue guidance to $85-87 billion, from $82-85 billion.

That is the spending wave fitness operators are selling alongside. Every point of adoption moves a consumer’s health budget, routine and expectations — and the category is compounding faster than any product line the industry has had to respond to in years.

Novo’s pill widens the funnel

Novo Nordisk’s second quarter told the complementary half of the story: adjusted operating profit of DKK 33,389 million on net sales of DKK 78,488 million, and an oral product changing the adoption curve. Weekly US prescriptions for the Wegovy pill exceeded 265,000 in the week ending 17 July 2026, and have passed five million since launch. The pill received European Medicines Agency approval in July 2026, with the OASIS 4 trial showing up to 16.6% mean weight loss — and up to 20.7% for the 7.2 mg dose. Novo raised its full-year 2026 outlook on increased expectations for GLP-1 sales, now guiding adjusted sales and operating-profit growth of 0% to -6% at constant exchange rates.

“The Wegovy® product portfolio remains a key growth driver for Novo Nordisk in 2026, led by the continued rapid adoption of Wegovy® pill in the US, which has reached more than 5 million prescriptions since its launch, alongside encouraging early uptake in markets outside the US and the rollout of Wegovy® HD (7.2 mg).”

— Mike Doustdar, President and CEO, Novo Nordisk

A pill at this scale moves GLP-1 therapy deeper into mainstream consumer routine — and into the member base of every operator.

The operator answer: resistance training and habits

The operators’ own data argues against treating the drugs as a churn sentence. Orangetheory’s survey work found that more than half of GLP-1 users say medication alone is not enough for lasting transformation, and the brand has built its response around resistance training and metabolic health. Coverage of operator responses also cites a University of Oxford review with a harder edge: weight regain after stopping GLP-1s often begins faster than after ending diet or exercise programs — which makes the training habit, not the prescription, the durable asset in the member relationship.

“Physiology and behavior are interconnected, but they are not the same thing. GLP-1s can influence appetite and body weight, but they don’t teach consistency, confidence or how to manage stress and recovery. We are optimistic that GLP-1s can be a catalyst for change, but they don’t change your environment.”

— Scott Brown, Vice President of Fitness, Orangetheory Fitness

The clubs crossover is direct — this programming shift lands on gym floors — but the corporate signal matters just as much: prescription volume is the leading indicator of GLP-1-member demand, and it is rising fast enough to plan against.

What to watch

Whether Lilly’s raised $85-87 billion guidance holds as the oral channel scales; whether the Wegovy pill’s five-million-prescription base converts into structured training uptake at the rate Orangetheory’s data implies; and whether operators standardise GLP-1-member programming — resistance work, metabolic health, habit coaching — before members conclude the drugs replace the gym. The prescription counters are public. The retention numbers will be private, and decisive.